aod9604 wada prohibited list status 2025 just added tirzepatide (mounjaro) to the 2026 Monitoring Program The World Anti-Doping Agency (WADA)

However, no controlled human trial has compared oral versus injectable AOD-9604 at equivalent systemic doses

High doses too frequently may lead to rare side effects like low potassium or vascular stress

Lipogenesis Effect The 5-amino-1MQ reduces lipogenesis framing is among the more evidence-supported aspects of the compounds profile

Depletion of the microbiome alters the recruitment of neuronal ensembles of oxycodone intoxication and withdrawal (in Eng)

If there is any uncertainty regarding the status of a substance or method, it is crucial to consult the relevant Anti-Doping Organisations or IFMA for guidance